Towards a specific diagnostic T-cell assay for COVID-19
SARS-CoV-2 is the causative agent of a pandemic of respiratory tract disease, referred to as coronavirus disease 2019 (COVID-19). To manage the ongoing outbreak, the consortium is entering a phase in which it is crucial to understand SARS-CoV-2-specific immunity on the individual and population level.
Detection of SARS-CoV-2-specific immune responses relies on antibody testing. However, asymptomatic and mild cases do not always develop antibodies and specific antibodies may not be long-lived. At the same time, virus-specific T-cell responses appear long-lived, detectable after asymptomatic infection, and after recovery from disease. Therefore, detection of SARS-CoV-2-specific T-cells could be a valuable marker for prior exposure to SARS-CoV-2.
SARS-CoV-2 is related to a number of seasonal coronaviruses endemic in humans that usually cause “common cold” symptoms (HCoVs). Several studies have shown that with the current technology, SARS-CoV-2-specific T-cells are also detected in individuals never exposed to SARS-CoV-2. This likely reflects the presence of so-called cross-reactive T-cells, i.e. T-cells induced by HCoVs that cross-recognise SARS-CoV-2. To study SARS-CoV-2-specific immunity on the individual and population level, it is of paramount importance that it is able to discriminate between T-cell responses that recognise SARS-CoV-2, HCoVs or both.
To this end, the consortium will generate unique discriminatory peptide pools and validate these in samples obtained from acute and convalescent COVID-19 patients, and unexposed control subjects. The consortium will also study the longevity of T-cell responses and follow a well-defined cohort for re-infections. The outcomes of this project will provide a fundamental understanding of T-cell responses to coronaviruses and contribute to answering questions about the role of coronavirus-specific T-cells in COVID-19. On the longer run, methods developed here potentially lead to a T-cell assay that could be employed as a diagnostic test to detect SARS-CoV-2 exposure, or to determine the ability of vaccines developed in the near future to induce T-cell responses.
This collaboration project is co-funded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to EMC to stimulate public-private partnerships. For questions, please contact EMC directly via the following email address firstname.lastname@example.org.